Zacks Investment Research on MSN17m
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Editas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...
Pharmaceutical Technology21m
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.